Revolution Medicines RVMD 深 沪
已收盘 08-01 16:00:00 美东时间
36.63
-0.640
-1.72%
华盛通- 最 高37.31
- 今 开37.00
- 成交量 98.51万股
- 最 低 36.44
- 昨 收 37.27
- 总市值 61.19亿
- 52周最高 62.40
- 市盈率 静 --
- 换手率 0.59%
- 52周最低 29.17
- 委 比 67.60%
- 总股本 1.67亿
- 历史最高 62.40
- 量 比 0.69
- 振 幅 2.33%
- 历史最低 14.08
- 每 手 1
- 风险率 5.78%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025
Revolution Medicines, Inc. (Nasdaq: RVMD) announced that it will report financial results for the second quarter of 2025 on August 6, 2025, after market close. A senior management team webcast discussing the results and corporate progress will follow at 4:30 p.m. ET (1:30 p.m. PT) that day. The live and archived webcast can be accessed at https://ir.revmed.com/events-and-presentations. The company develops RAS(ON) inhibitors targeting RAS-addicte...
07-30 20:05
Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor
Revolution Medicines announced the publication of a research paper in *Science* detailing zoldonrasib (RMC-9805), a RAS(ON) G12D-selective covalent inhibitor targeting oncogenic RAS G12D mutations. These mutations are common in cancers like pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Zoldonrasib leverages a novel mechanism involving a protein-protein interface to selectively inhibit RAS G12D, showing promi...
07-24 20:00
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses
Castle Biosciences (NASDAQ:CSTL) said on Wednesday that it has received breakthrough device designation from the U.S. Food and Drug Administration for its DecisionDx-Melanoma test. The DecisionDx-Mel...
07-23 21:18
Revolution Medicines Says FDA Grants Breakthrough Therapy Designation To Elironrasib For Treatment Of Adult Patients With KRAS G12C-Mutated Locally Advanced Or Metastatic NSCLC
Breakthrough Therapy Designation granted to elironrasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received prior chemotherapy and
07-23 20:02
Revolution Medicines And Iambic Therapeutics Partner To Develop Novel Drug Candidates Using AI Models In Multi-Year Collaboration; Iambic To Receive Up To $25M Through A Combination Of Upfront And Expected Near-Term Performance-Based Milestone Payments For Services Related To Revolution Medicines' Access To Iambic's NeuralPLexer Model For Protein Structure Prediction
Custom-built model will be trained using Revolution Medicines' proprietary data to discover novel drug candidatesIambic to receive up to $25 million through a combination of upfront and expected near-term
07-09 20:16
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
Revolution Medicines and Iambic Therapeutics have entered a multi-year collaboration to develop novel drug candidates using Iambic’s AI models, including NeuralPLexer for protein structure prediction. Under the agreement, Iambic will receive up to $25 million in payments, and both companies will retain rights to exclusive targets. The partnership aims to address challenging oncology targets in RAS-addicted cancers, leveraging Iambic’s advanced AI...
07-09 12:00
Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors
Revolution Medicines and Summit Therapeutics have entered a clinical collaboration to evaluate the safety and efficacy of Revolution's RAS(ON) inhibitors, including daraxonrasib, zoldonrasib, and elironrasib, in combination with Summit's ivonescimab, a PD-1/VEGF bispecific antibody. The collaboration focuses on three tumor types: RAS mutant non-small cell lung cancer, pancreatic ductal adenocarcinoma, and colorectal cancer. Summit will supply ivo...
06-30 12:00
美股大行评级 | 潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
潜在涨幅312.09%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级；联邦快递遭多家机构下调目标价>>
06-26 08:38
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
Revolution Medicines dips 5%, gets $2B flexible funding
A late-stage clinical oncology company, Revolution Medicines (NASDAQ:RVMD) partnered with Royalty Pharma on $2B in flexible funding to support its product development and commercialization for its p...
06-24 19:36
